Physician profile
James E Ehrlich
NPI 1073728630
$1,737.80
in general payments reported to CMS, 2019-2025
15 companies · $619 in 2025
The $619 reported for 2025 was more than what 82% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $104 · 2021: $112 · 2022: $513 · 2023: $99.45 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $600.73 | 2019-2025 | Otezla, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company Ltd. | $265.11 | 2022 | |
| Novo Nordisk INC | $180.38 | 2023-2025 | Wegovy, Ozempic |
| Cleerly, INC. | $130.39 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Edwards Lifesciences Corporation | $123.32 | 2025 | Sapien 3 Ultra Resilia |
| Eisai INC. | $112.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $100.00 | 2019 | |
| Amarin Pharma, INC. | $68.52 | 2019 | |
| Lilly USA, LLC | $30.77 | 2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.51 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $24.11 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.14 | 2022 | |
| Exact Sciences Corporation | $19.98 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.74 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $14.91 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.